



**XIth International
Myeloma Workshop**
& **IVth International Workshop
on Waldenström's
Macroglobulinemia**

Kos Island, Greece, 25-30 June 2007

Organized by:

Department of Clinical Therapeutics

Alexandra Hospital

Medical School

National & Kapodistrian University of Athens

***IVth International
Workshop on Waldenström's
Macroglobulinemia***

Scientific Programme

*IVth International Workshop on
Waldenström's Macroglobulinemia
Scientific Programme*

Friday, June 29, 2007

Hall Hippocrates

14:00-14:30		Opening Addresses - Kyle Award
14:30-16:50	WM1	Genetics, Pathophysiology and Staging System Chair: M.A. Dimopoulos, Greece - S. Treon, USA
14:30-14:50	WM1.1	G.A. Pangalis, Greece Biologic and clinical overlap of IgM-Secreting lymphomas; Focus on Waldenström's Macroglobulinemia (WM)
14:50-15:10	WM1.2	S.S. Sahota, United Kingdom : Tracking the malignant cell of origin in Waldenström's Macroglobulinemia
15:10-15:30	WM1.3	R. Garcia-Sanz, Spain : Immunoglobulin gene rearrangements in WM
15:30-15:50	WM1.4	L.M. Pilarski, Canada : Inherited and acquired mutations in Waldenström's Macroglobulinemia (WM): WM and MM have a close genetic relationship not shared with B-CLL
15:50-16:10	WM1.5	R. Fonseca, USA : Genetics and Genomics of Waldenström Macroglobulinemia
16:10-16:30	WM1.6	E. Morra, Italy : IgM MGUS and Asymptomatic WM: Prognostic factors and evolution
16:30-16:50	WM1.7	P. Morel, France : International prognostic scoring system for Waldenström's Macroglobulinemia
17:00-18:00		Poster Session III

*Saturday, June 30, 2007**Hall Hippocrates*

- 08:00-10:00 WM2 **Frontline treatment of WM**
Chair: M. Gertz, USA
- 08:00-08:20 WM2.1 **R.A. Kyle, USA:**Indications for treatment and the role of Alkylating agents in WM
- 08:20-08:40 WM2.2 **V. LeBlond, France:**Role of purine analogs in front-line treatment of Waldenström's Macroglobulinemia
- 08:40-09:00 WM2.3 **D.M. Weber, USA:**Rituximab alone or in combination in the frontline treatment of WM
- 09:00-09:20 WM2.4 **M.A. Gertz, USA:**Overview in salvage treatment in WM
- 09:20-09:40 WM2.5 **A. Anagnostopoulos, Greece:**The role of autologous transplantation in WM
- 09:40-10:00 WM2.6 **S.P. Treon, USA:**Novel agents in the treatment of Waldenström's Macroglobulinemia: Update of WMCTG Clinical Trials
- 10:00-10:30 Coffee Break

Hall Hippocrates

- 10:30-13:20 WM3 **Novel treatment approaches, treatment of advanced disease**
Chair: V. LeBlond, France - A. Anagnostopoulos, Greece
- 10:30-10:50 WM3.1 **I. Ghobrial, USA:**Proteomic analysis in WM
- 10:50-11:05 WM3.2 **N.C. Gutierrez, Spain:**The gene expression signature of clonal cells from Waldenström's Macroglobulinemia: differences and commonalities with the normal cell counterpart and other related lymphoproliferative disorders
- 11:05-11:20 WM3.3 **E. Hatjiharissi, USA:**Gene expression profiling of Waldenström's Macroglobulinemia reveals genes that may be related to disease pathogenesis

Saturday, June 30, 2007 ■

Hall Hippocrates

- 11:20-11:35 WM3.4 **E. Hatjiharissi, USA**: Novel splice variant transcript of Siva in Waldenström's Macroglobulinemia
- 11:35-11:50 WM3.5 **S. Adamia, USA**: Aberrant post-transcriptional regulation of TNF family members and their adaptor molecules essential to B-cell growth and survival in Waldenström's Macroglobulinemia
- 11:50-12:05 WM3.6 **B.T. Ciccarelli, USA**: The functional role of CD27-CD70 interactions in Waldenström's Macroglobulinemia
- 12:05-12:20 WM3.7 **A. Anagnostopoulos, Greece**: Serum concentrations of angiogenic cytokines in Waldenström's Macroglobulinemia: The ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity
- 12:20-12:35 WM3.8 **J. Soumerai, USA**: Use of the immunomodulators thalidomide and lenalidomide to augment rituximab clinical activity in Waldenström's Macroglobulinemia
- 12:35-12:50 WM3.9 **C. Kyriakou, United Kingdom**: Allogeneic stem cell transplantation (ALLO-SCT) in Waldenström's Macroglobulinemia (WM). An analysis of 106 cases from the European Bone Marrow Registry (EBMT)
- 12:50-13:05 WM3.10 **X. Leleu, USA**: Increased incidence of disease transformation and development of MDS/AML in Waldenström's Macroglobulinemia (WM) patients treated with nucleoside analogues.
- 13:05-13:20 WM3.11 **A.D. Wechalekar, United Kingdom**: Clinical Profile And Treatment Outcome In 103 Patients With AL Amyloidosis Associated With IgM Paraproteinemia

13:20-14:30 Lunch Break

Hall Hippocrates

14:30-16:30

Consensus on WM treatment

Chair: S.P. Treon, USA - M.A. Dimopoulos, Greece